Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease: An Analysis of Clinical Benefit As Determined By Number Needed to Treat (NNT) to Achieve Complete Response and to Improve Survival
Publication
, Conference
Richardson, PG; Kernan, NA; Grupp, SA; Martin, PL; Soiffer, RJ; Martin, R; Hannah, A; Villa, KF
Published in: Biology of Blood and Marrow Transplantation
February 2015
Duke Scholars
Published In
Biology of Blood and Marrow Transplantation
DOI
ISSN
1083-8791
Publication Date
February 2015
Volume
21
Issue
2
Start / End Page
S110 / S110
Publisher
Elsevier BV
Related Subject Headings
- Immunology
- 3201 Cardiovascular medicine and haematology
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Richardson, P. G., Kernan, N. A., Grupp, S. A., Martin, P. L., Soiffer, R. J., Martin, R., … Villa, K. F. (2015). Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease: An Analysis of Clinical Benefit As Determined By Number Needed to Treat (NNT) to Achieve Complete Response and to Improve Survival. In Biology of Blood and Marrow Transplantation (Vol. 21, pp. S110–S110). Elsevier BV. https://doi.org/10.1016/j.bbmt.2014.11.138
Richardson, Paul G., Nancy A. Kernan, Stephan A. Grupp, Paul L. Martin, Robert J. Soiffer, Richard Martin, Alison Hannah, and Kathleen F. Villa. “Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease: An Analysis of Clinical Benefit As Determined By Number Needed to Treat (NNT) to Achieve Complete Response and to Improve Survival.” In Biology of Blood and Marrow Transplantation, 21:S110–S110. Elsevier BV, 2015. https://doi.org/10.1016/j.bbmt.2014.11.138.
Richardson PG, Kernan NA, Grupp SA, Martin PL, Soiffer RJ, Martin R, et al. Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease: An Analysis of Clinical Benefit As Determined By Number Needed to Treat (NNT) to Achieve Complete Response and to Improve Survival. In: Biology of Blood and Marrow Transplantation. Elsevier BV; 2015. p. S110–S110.
Richardson, Paul G., et al. “Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease: An Analysis of Clinical Benefit As Determined By Number Needed to Treat (NNT) to Achieve Complete Response and to Improve Survival.” Biology of Blood and Marrow Transplantation, vol. 21, no. 2, Elsevier BV, 2015, pp. S110–S110. Crossref, doi:10.1016/j.bbmt.2014.11.138.
Richardson PG, Kernan NA, Grupp SA, Martin PL, Soiffer RJ, Martin R, Hannah A, Villa KF. Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease: An Analysis of Clinical Benefit As Determined By Number Needed to Treat (NNT) to Achieve Complete Response and to Improve Survival. Biology of Blood and Marrow Transplantation. Elsevier BV; 2015. p. S110–S110.
Published In
Biology of Blood and Marrow Transplantation
DOI
ISSN
1083-8791
Publication Date
February 2015
Volume
21
Issue
2
Start / End Page
S110 / S110
Publisher
Elsevier BV
Related Subject Headings
- Immunology
- 3201 Cardiovascular medicine and haematology
- 1103 Clinical Sciences